Cancer vaccine developer Juvaris raises $7.53M, led by Kleiner Perkins

Juvaris BioTherapeutics, a Pleasanton, Calif. developer of vaccines for cancer and infectious diseases, has raised $7.53 million in a first round of funding led by Kleiner Perkins Caufield & Byers, according to a regulatory filing cited by PE Wire.

Tom Monath of KPCB will serve on the Juvaris board of directors. Juvaris had said on its website that it was seeking “$10 million to commence full-scale operations.” Company CEO Martin Cleary declined to comment.